A Multicenter, International, Randomized, Placebo Controlled, Double-Blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-Cardioembolic Ischemic Stroke or High-Risk TIA (OCEANIC)
Protocol Number: 15579
Status: Open
Age Group: Adult
Treatment Type: Prevention
Secondary Protocol No.: BAY 2433334 (asundexian) / 20604
